Clinical Insights From Ocugen’s OCU410 Gene Therapy for Dry AMD and Geographic Atrophy
Time: 9:00 am
day: Day1
Details:
- Characterizing Vector and promoter selection – ensuring compatibility with target retinal layers and pathologic processes
- Exploring strategies to minimize immunogenicity and dosing risk in elderly populations
- Unpacking the latest updates from the ArMaDa Phase ½ trial, discussing early safety signals, trial design for GA populations and long-term potential for slowing disease progression
